28.93
0.59 (2.08%)
| Previous Close | 28.34 |
| Open | 28.66 |
| Volume | 1,799,472 |
| Avg. Volume (3M) | 2,114,714 |
| Market Cap | 2,935,670,272 |
| Price / Sales | 46.72 |
| Price / Book | 2.91 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -1,596.87% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Total Debt/Equity (MRQ) | 14.08% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -351.38 M |
| Levered Free Cash Flow (TTM) | -185.90 M |
| Return on Assets (TTM) | -19.05% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Beam Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 0.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 1.10 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.22% |
| % Held by Institutions | 98.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Arch Venture Management, Llc | 30 Sep 2025 | 4,540,132 |
| Mwg Management Ltd. | 30 Sep 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 176.53%) | Buy |
| Median | 35.00 (20.98%) | |
| Low | 28.00 (UBS, -3.22%) | Hold |
| Average | 47.67 (64.78%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 26.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 28.00 (-3.21%) | Hold | 28.93 |
| Evercore ISI Group | 24 Nov 2025 | 35.00 (20.98%) | Buy | 23.62 |
| HC Wainwright & Co. | 10 Oct 2025 | 80.00 (176.53%) | Buy | 26.32 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BELLON CHRISTINE | - | 27.72 | -1,254 | -34,761 |
| EMANY SRAVAN KUMAR | - | 27.72 | -6,294 | -174,470 |
| SIMON AMY | 27.72 | - | 12,500 | 346,500 |
| Aggregate Net Quantity | 4,952 | |||
| Aggregate Net Value ($) | 137,269 | |||
| Aggregate Avg. Buy ($) | 27.72 | |||
| Aggregate Avg. Sell ($) | 27.72 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SIMON AMY | Officer | 31 Dec 2025 | Acquired (+) | 12,500 | 27.72 | 346,500 |
| BELLON CHRISTINE | Officer | 31 Dec 2025 | Automatic sell (-) | 1,254 | 27.72 | 34,761 |
| EMANY SRAVAN KUMAR | Officer | 31 Dec 2025 | Automatic sell (-) | 6,294 | 27.72 | 174,470 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |